- 93.5k views
Beyond Breathless: Innovative Approaches to PAH Management
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
About the Speaker
Dr. Bhagwan Mantri
Consultant Pulmonologist and Critical care specialist
Upcoming Case Discussions
Technology Integration with Healthcare
Technology integration in healthcare is transforming the way medical services are delivered, enhancing efficiency and patient outcomes. Innovations such as telemedicine, electronic health records (EHR), and wearable devices allow for real-time monitoring and improved accessibility. Artificial intelligence (AI) and machine learning aid in early diagnosis and personalized treatment plans. Robotic surgeries and advanced imaging techniques offer precision and reduced recovery times. By combining technology with healthcare, providers can streamline operations, improve patient engagement, and deliver cost-effective care solutions.
Pediatric Obesity: Treatment Management
Treatment management for pediatric obesity combines lifestyle changes, family support, and, in severe cases, medical interventions. Family-based strategies are key, encouraging healthy eating habits, regular physical activity, and reduced screen time. Behavioral therapy helps set achievable goals and address barriers, empowering children and families to make sustainable lifestyle adjustments. Dietitians often assist in designing individualized meal plans that focus on nutrient-rich foods and limit calorie-dense options. In cases of severe obesity with related health conditions, medications or surgery may be considered, particularly for adolescents. Continuous monitoring and support from healthcare providers are essential for long-term success and health improvement.
Clinician’s Approach to Sleep Apnea
A clinician's approach to sleep apnea begins with a thorough assessment of the patient's medical history, symptoms (such as snoring, choking, and daytime fatigue), and risk factors like obesity or hypertension. Diagnosis is typically confirmed through polysomnography or home sleep apnea testing, followed by treatment strategies such as continuous positive airway pressure (CPAP), lifestyle modifications, or surgical interventions depending on the severity and type of sleep apnea.
Case Based Approach to Arthritis
A case-based approach to arthritis involves analyzing individual patient cases to tailor diagnostic and therapeutic strategies based on specific symptoms, disease progression, and underlying causes. This method enhances clinical decision-making by providing personalized treatment plans and improving patient outcomes in conditions like osteoarthritis, rheumatoid arthritis, and psoriatic arthritis.
Falls and Fractures in Older Adults: Prevention and Immediate Care
Falls and fractures in older adults are common and can lead to significant morbidity, highlighting the importance of fall prevention strategies such as strength training, balance exercises, and home safety modifications. Immediate care involves quick assessment for fractures, pain management, and stabilization, along with appropriate transport to healthcare facilities for further evaluation and treatment.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Bhagwan Mantri's Talks on Assimilate
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.
- 18th-May-2023, TIME : 6:00PM - 7:00PM
- 0
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that affects the arteries in the lungs, leading to increased pulmonary arterial pressure and right heart failure. Despite significant advances in the management of PAH in recent years, it remains a challenging disease to treat, and many patients continue to experience significant symptoms and reduced quality of life. However, there are several innovative approaches to PAH management that are currently being explored and show promise in improving outcomes for patients. One such approach is the use of combination therapy. While single-agent therapy has traditionally been the first-line treatment for PAH, recent studies have shown that combining different classes of drugs can lead to better outcomes. For example, combining an endothelin receptor antagonist with a phosphodiesterase type 5 inhibitor has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH. Another promising approach is the use of novel drugs that target specific pathways involved in the development of PAH. For example, selexipag, a prostacyclin receptor agonist, has been shown to improve exercise capacity and reduce hospitalization rates in patients with PAH. Similarly, macitentan, a dual endothelin receptor antagonist, has been shown to improve exercise capacity and reduce clinical worsening in patients with PAH.